2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2030

A Multi-Modal Amplified Musculoskeletal Pain Treatment Program: Associations of Previous Pharmacotherapy with Subsequent Outcomes
Abstract Number: 776

A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission
Abstract Number: 1409

A Multicentre Clinical Study of Umbilical Cord Mesenchymal Stem Cells Transplantation in Active Systemic Lupus Erythematosus
Abstract Number: 920

A Multimodal Intervention to Improve Osteoporosis Care in Home Health Settings: Results From a Cluster Randomized Trial
Abstract Number: 1009

A New Approach for Detecting Progressive Joint Damage Using 3D Imaging From High-Resolution Peripheral Quantitative Computed Tomography: Measuring Reproducibility
Abstract Number: 1938

A New Enzyme-Linked Immunosorbent Assay System for Detecting Autoantibodies to Aminoacyl-tRNA Synthetases: Clinical Usefulness in Myositis and Interstitial Pneumonia
Abstract Number: 1956

A New Linked Set of Autoantibodies in Dermatomyositis: Anti-Mi-2 and Anti-Transcription Intermediary Factor (TIF) 1alpha
Abstract Number: 1155

A New Measure of Visual Function for Children with Juvenile Idiopathic Arthritis-Associated Uveitis
Abstract Number: 511

A New Pathogenic Role of Salivary Gland Epithelial Cells in the Costimulation of T Lymphocytes in Primary Sjögren’s Syndrome: 0X40 Ligand Expression, T-Cell Induction of OX40 and Promotion of T-Cell Survival, Proliferation and Activation
Abstract Number: 1806

A Novel Angiopoetin2/TEK Tyrosine Kinase Receptor Mediated Effect On Leukocyte Cell Influx and Oxidative Damage in Inflammatory Arthritis
Abstract Number: 1592

A Novel Approach to the Early Detection of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease: The Implementation of an Advanced Practice Physiotherapist Led Screening Program
Abstract Number: 676

A Novel Biomarker: Nucleotide-Binding Oligomerization Domain 27 in Systemic Lupus Erythematosus
Abstract Number: 1311

A Novel Individualized Treatment Approach in Open-Label Extension Study of Ozoralizumab (ATN-103) in Subjects with Rheumatoid Arthritis On a Background of Methotrexate
Abstract Number: 2328

A Novel Method for Quantitative and Functional Analysis of Autophagy Using Flow Cytometry in Activated Human Primary T Cells
Abstract Number: 2019

A Novel MRI Scoring System for the Evaluation of Early-Stage Disease Activity of the Wrist in Juvenile Idiopathic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].